AGE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AGE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of AgeX Therapeutics is: No Data: Cannot be evaluated.
For the Biotechnology subindustry, AgeX Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AgeX Therapeutics's Risk Assessment distribution charts can be found below:
* The bar in red indicates where AgeX Therapeutics's Risk Assessment falls into.
AgeX Therapeutics (AMEX:AGE) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of AgeX Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Jean-christophe Renondin | director | 505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022 |
Juvenescence Us Corp. | director, 10 percent owner | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Joanne M. Hackett | director | C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708 |
Park Andrea Eun Jae | officer: Chief Financial Officer | C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501 |
Michael H May | director | 965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501 |
Michael D West | director, officer: Chief Executive Officer | AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501 |
Michael H. Mulroy | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
Russell Skibsted | officer: Chief Financial Officer | 15 TRANQUILITY PLACE, LADERA RANCH CA 92694 |
Judith Segall | officer: Corporate Secretary | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Hal Sternberg | officer: Vice President-Research | 935 PARDEE STREET, BERKELEY CA 94710 |
Annalisa Jenkins | director | C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555 |
John F Mauldin | director | 3204 BEVERLY DRIVE, DALLAS TX 75205 |
Gregory Bailey | director | 4 A CHESHAM STREET, LONDON X0 SW1X8DT |
Juvenescence Ltd | 10 percent owner | 1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB |
Nafees Naseer Malik | officer: Chief Operating Officer | C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501 |
From GuruFocus
By PRNewswire • 10-10-2023
By PRNewswire • 09-06-2023
By PRNewswire • 10-24-2023
By Marketwired • 09-15-2023
By PRNewswire • 09-19-2023
By Marketwired • 08-30-2023
By Marketwired • 10-18-2023
By PRNewswire • 10-24-2023
By PRNewswire • 08-30-2023
By PRNewswire • 09-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.